HELICOBACTER PYLORI ERADICATION IN PATIENTS WITH COMBINATION OF CHRONIC GASTRITIS AND DIABETES MELLITUS II TYPE
DOI:
https://doi.org/10.11603/1811-2471.2018.v0.i1.8482Keywords:
2 diabetes mellitus, chronic gastritis, helicobacter pylori, antihelicobacter therapy, Saccharomyces boulardii.Abstract
Helicobacter pylori (HP) is a major bacterial pathogen, which leads to the development of chronic infection and can cause a number of diseases of the upper gastrointestinal tract. The prevalence of HP is significantly higher in patients with type 2 diabetes mellitus (DM) compared with patients without type 2 diabetes.
The aim of the study – to evaluate the effectiveness of the SB in complex anti-helicobacter therapy (AHT) in patients with chronic gastritis (CG) in combination with DM 2 type.
Material and Methods. 42 HP positive patients were examined with a combination of DM 2 type and CG. The average age of patients was 53.6±1.4 years. There were 13 (30.9 %) women and 29 (69.1 %) men patients. Patients were divided into 2 groups: I group (n=21) received only standard AHT, group II (n=21) in addition to the AHT received the SV (Normagut, Mega) 2 capsules 2 times a day – 14 days.
Results. The following results were obtained, namely the connection between insulin resistance and presence of HP in the body was observed, and its eradication subsequently leads to an improvement in insulin sensitivity. According to analysis of patients complaints examined before and at the end of 2 weeks of AHT, improvement of the status of patients in group ІІ, taken additionally to standard therapy SB was found. The improvement of glucose control in patients with DM 2 type and CG can be reached by effective eradication of HP.
Conclusions. Eradication of HP is important in patients with DM 2 type and CG, since AHT promotes insulin sensitivity.
References
American College of Gastroenterology guideline on the management of Helicobacter pylori infection / W.D. Chey, B.C. Wong // The American journal of gastroenterology – 2007. - 102(8). – 1808
Association between Helicobacter pylori infection and diabetes mellitus: a meta-analysis of observational studies / X. Zhou, C. Zhang, J. Wu, G. Zhang // Diabetes Research and Clinical Practice – 2013. – 99 (2). – P.200-208.
Helicobacter pylori infection is associated with an increased rate of diabetes / C.Y. Jeon, M.N. Haan, C. Cheng, E.R. Clayton, E.R. Mayeda, J.W. Miller A.E. Aiello // Diabetes care – 2012. – 35(3). – P.520-525.
Effects of leptin and adiponectin on pancreatic β-cell function / Y.H. Lee, F. Magkos, C.S. Mantzoros, E.S. Kang // Metabolism – Clinical and Experimental – 2011. – 60(12). - P.1664-1672.
Cytokines in the progression of pancreatic β-cell dysfunction / C. Wang, Y. Guan, J. Yang //International journal of endocrinology – 2010.
Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis / M.M. Zhang, W. Qian, Y.Y. Qin, J. He, Y.H. Zhou // World Journal of Gastroenterology: WJG – 2015. - 21 14). – P. 4345.
Review of the role of probiotics in gastrointestinal diseases in adults / J.J.S. Domingo // Gastroenterología y Hepatología (English Edition) – 2017. – 40(6). – P. 417-429.
Management of Helicobacter pylori infection—the Maastricht V/ P. Malfertheiner, F. Megraud, C.A. O'morain, J.P. Gisbert, E.J. Kuipers, A.T. Axon, ... & R. Hunt // Florence consensus report. Gut, gutjnl – 2016.
